Welcome to our dedicated page for Eliem Therapeutics SEC filings (Ticker: ELYM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Eliem Therapeutics’ disclosures can feel like a lab notebook written in legalese—hundreds of pages on R&D burn, clinical milestones, and shelf registrations that move the share count overnight. If you are searching for Eliem Therapeutics SEC filings explained simply, this page turns dense reports into clear, actionable insights.
Our AI reviews every submission the moment it hits EDGAR. Whether it is an Eliem Therapeutics annual report 10-K simplified that breaks down CD19-antibody trial costs, an Eliem Therapeutics quarterly earnings report 10-Q filing highlighting cash runway, or an Eliem Therapeutics 8-K material events explained summarizing interim study data, you get a concise brief plus the full document. Real-time alerts flag Eliem Therapeutics Form 4 insider transactions real-time so you can track executive stock moves alongside detailed Eliem Therapeutics insider trading Form 4 transactions tables. Still comparing compensation packages? Our platform links directly to the Eliem Therapeutics proxy statement executive compensation section.
Here’s how professionals use these tools:
- Run instant Eliem Therapeutics earnings report filing analysis to gauge clinical spending trends.
- Set notifications for Eliem Therapeutics executive stock transactions Form 4 before pivotal data releases.
- Follow every immunology program update through AI-tagged exhibits in 10-Q, 10-K, and 8-K forms.
- Save hours by understanding Eliem Therapeutics SEC documents with AI rather than parsing footnotes manually.
Every filing—10-K, 10-Q, 8-K, S-3, even the latest Eliem Therapeutics proxy statement—is indexed, summarized, and updated in real time. Complex biotech disclosures become clear so you can focus on making informed decisions, not decoding jargon.
Climb Bio, Inc. reported a net loss of $8.7 million for Q2 2025 and $29.4 million for the six months ended June 30, 2025. The company held $22.7 million in cash and $164.0 million in marketable securities (short- and long-term combined), giving available cash, cash equivalents and marketable securities of approximately $187.4 million as of June 30, 2025. Climb Bio had 67.8 million shares outstanding.
The period reflected increased research and development spending related to budoprutug and the CLYM116 license, including a $9.0 million upfront payment under the Mabworks agreement and higher clinical start-up and manufacturing costs for budoprutug after the Tenet acquisition. The company recorded prior acquired IPR&D expense of $51.7 million tied to the June 2024 Tenet acquisition. Management states current resources are expected to fund operations through 2027.
Climb Bio, Inc. announced it furnished a press release reporting its financial results for the quarter ended June 30, 2025. The press release is attached as Exhibit 99.1 and the company states the information is being furnished and not filed for purposes of Section 18 of the Exchange Act, meaning it is provided to investors but not incorporated into other filings by reference.
The company’s common stock trades on The Nasdaq Stock Market under the ticker CLYM. The report is signed on behalf of the registrant by Aoife Brennan, M.B., Ch.B., President and Chief Executive Officer. Financial details themselves are contained in the attached press release.
Thomas Stephen Basil, a director of Climb Bio, Inc. (CLYM), had restricted stock units granted on June 27, 2024 vest after performance milestones were deemed achieved on 08/07/2025, resulting in the acquisition of 100,375 shares of common stock. The award was settled at a $0 per-share price as reported.
Following the vesting event, Mr. Basil's direct beneficial ownership increased to 304,657 shares. The Form 4 discloses that the RSUs were subject to performance-based milestones and continuous service and that the milestones were deemed achieved, causing full vesting of the award.
FAQ
What is the current stock price of Eliem Therapeutics (ELYM)?
What is the market cap of Eliem Therapeutics (ELYM)?
